Please provide your email address to receive an email when new articles are posted on . Imuldosa, an ustekinumab biosimilar, is approved for multiple inflammatory diseases, including Crohn’s disease ...

Please provide your email address to receive an email when new articles are posted on . Selarsdi, an ustekinumab biosimilar, is now approved Crohn’s disease and ulcerative colitis. The drug is ...

Imuldosa, a Stelara biosimilar, is approved for autoimmune diseases, marking the fifth ustekinumab biosimilar in the US market. Stelara, a top-grossing biologic, underwent CMS price negotiations with ...

On March 12, 2025, Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab), in the United States. As we previously reported, the ...

Johnson & Johnson filed a lawsuit in a New Jersey federal court, against Samsung Bioepis for breaching its contract agreement with the company over the launch of a biosimilar to its autoimmune drug ...

The Food and Drug Administration has approved Celltrion's Steqeyma (ustekinumab-stba), a biosimilar to Johnson & Johnson's Stelara (ustekinumab), for subcutaneous injection or intravenous infusion in ...

A biosimilar version of the multipurpose biologic drug ustekinumab has been approved by the FDA and can be swapped interchangeably with the original product sold as Stelara. The new version carries ...

Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...